Patricia LoRusso, Toru Mukohara, David Sommerhalder, Kan Yonemori, Erika P. Hamilton, Rachel M. Layman, Sung-Bae Kim, Seock-Ah Im, Hope S. Rugo, Toshinari Yamashita, Fengting Yan, Fumikata Hara, Gun Min Kim, Shusen Wang, Sean Kent, Li Liu, Athanasia Skoura, Karen Kowalski, Meng Li, Yeon Hee Park. "Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.1020